Bitfarms executives detailed a strategic pivot from Bitcoin mining to HPC/AI data centers, citing power and infrastructure as key constraints. The company plans a 'build first, price later' approach, designs for NVIDIA's Vera Rubin GPUs, and expects key U.S. sites to reach construction approval in late 2026.
Visa integrates BVNK's stablecoin infrastructure into its Visa Direct platform, enabling businesses to send payouts in stablecoins to digital wallets, starting in high-demand markets.
A 64-year-old with $650,000 in a traditional IRA explores gradual Roth conversions to manage required minimum distributions and future tax liabilities.
Amazon will appeal an Italian court decision that reduced a fine for antitrust violations. The regulator also plans to appeal the reduction.
China's auto exports rose 21% in 2025, driven by electric vehicles, while domestic demand weakened, according to industry data.
Saks Global, owner of Saks Fifth Avenue and Neiman Marcus, filed for Chapter 11 bankruptcy, citing debt from its 2024 acquisition and rising competition. The company secured $1.75 billion in financing and says stores will stay open.
Revolut processed over $10.5 billion in stablecoin payments by December 2025, a 156% annual increase, driven by cross-border transfers and low fees.
Monday.com stock fell 37.3% in 2025, driven by AI disruption fears, but the company reported 26% revenue growth and increased high-value customers.
Wedbush raised Praxis Precision Medicines' price target to $95 on Jan. 12, maintaining an Underperform rating despite a recent $621M offering. Wall Street consensus remains Strong Buy.
Immunome shares rose 48% in three months after Phase 3 trial results for desmoid tumor drug Varegacestat showed 84% reduced progression risk. FDA approval sought in 2026.
Goldman Sachs upgraded Crinetics Pharmaceuticals to Buy after trial data showed a 67% reduction in A4 for CAH. Citizens also reported positive early experience with Palsonify, supporting Q4 revenue.
Wolfe Research downgraded Kymera Therapeutics to Peer Perform on January 6, removing its $92 price target, while BTIG and Citigroup maintained Buy ratings. The stock had gained over 28% in three months, with Wall Street anticipating further growth.
Personal finance expert Dave Ramsey criticized widespread financial advice as misleading, citing historical inflation and income data to argue economic conditions are manageable.
Vera Therapeutics announced FDA priority review for Atacicept's BLA to treat IgAN, with a target action date of July 7, 2026. CEO Marshall Fordyce highlighted its potential as a first-in-class B-cell modulator.
Edgewise Therapeutics shares rose 3% on January 13 after outlining 2026 priorities, including key drug trial milestones. Analysts maintain positive ratings.